Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ingvar Karlsson is active.

Publication


Featured researches published by Ingvar Karlsson.


Dementia and Geriatric Cognitive Disorders | 2001

Treatment of Alzheimer’s Disease with Clioquinol

Björn Regland; Werner Lehmann; Iraj Abedini; Kaj Blennow; Michael Jonsson; Ingvar Karlsson; Magnus Sjögren; Anders Wallin; Michel Xilinas; Carl-Gerhard Gottfries

As heavy metal ions may be implicated in the formation of senile plaques in Alzheimer-afflicted brains, treatment with clioquinol was tested in 20 patients with Alzheimer’s disease. Clioquinol is a chelator that crosses the blood-brain barrier and has greater affinity for zinc and copper ions than for calcium and magnesium ions. Treatment was given for 21 days at doses of 20 mg/day to 10 patients and 80 mg/day to another 10 patients. The study was blind to the dosages but included no controls. Cerebrospinal fluid (CSF) investigations revealed a significant increase at day 7 and a decrease at day 21 in Tau protein and growth-associated protein (GAP43). These proteins are increased in Alzheimer’s disease and considered as rather stable markers. The initial increase may indicate a temporary cytotoxicity to the brain and/or an increased release into the CSF from stores in the tissue, possibly from senile plaques where the proteins are accumulated. The levels of CSF-Tau protein correlated positively and significantly with the serum levels of copper and also with the serum copper/zinc ratio. Clinical ratings showed slight improvement after 3 weeks treatment with clioquinol in this open study.


Acta Neurologica Scandinavica | 2009

Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors

Kaj Blennow; Anders Wallin; Pam Fredman; Ingvar Karlsson; C. G. Gottfries; Lars Svennerholm

To investigate the blood‐brain barrier (BBB function), serum and cerebro‐spinal fluid (CSF) from 118 patients with Alzheimers disease (AD) and 50 healthy controls was analyzed with regard to albumin concentrations. For the AD group, clinical vascular factors were also recorded. The CSF/serum albumin ratio was used as a measure of BBB function. When compared with controls, the AD group showed a higher mean albumin ratio, indicating a decline in BBB function. However, no significant reduction in BBB function was found in AD patients without vascular factors. These findings support the hypothesis that BBB disturbance is related to vascular factors, coexisting with AD. In the control group, no significant correlation between age and albumin ratio was found, which suggests that aging per se is not primarily associated with a decline in BBB function. The present study provides evidence in favour of the conclusion that a reduced BBB function is related neither to AD nor to aging, but to clinical vascular factors.


Dementia and Geriatric Cognitive Disorders | 1994

The neurochemistry of vascular dementia.

C. G. Gottfries; Kaj Blennow; Ingvar Karlsson; Åsa K. Wallin

Vascular dementia (VAD) is cognitive impairment caused by changes in the blood circulation of the brain. It is not synonymous with multi-infarct dementia. The latter is a subgroup of VAD. Neurochemical investigations of noninfarcted brain tissue from patients with VAD show general changes in VAD brains. The serotonin metabolism is severely reduced and so is the activity of choline acetyltransferase. Monamine oxidase B is significantly increased in the white matter. A severe decrease in myelin components indicates white matter disturbances of such a degree that they must be considered to be of pathogenetic importance. The levels of some neuropeptides in the hypothalamus are increased. This is a finding which is in agreement with clinical findings of a high activity in the hypothalamic-pituitary-adrenal axis in patients with VAD. This high activity is possibly due to a loss of serotonergic inhibitory tone on the hypothalamus in VAD brains.


Clinical Nursing Research | 1996

Dinner music for demented patients: analysis of video-recorded observations.

Hans Ragneskog; Mona Kihlgren; Ingvar Karlsson; Astrid Norberg

At a nursing home ward for demented patients, selections of dinner music were played during three periods of 2 weeks. At the end of the study was a control period. The reactions of five patients to three different types of music were registered by video observations. This study showed that the patients were affected by music, particularly soothing music. For example, it was found that when music was played one of the studys restless patients became unusually calm whereas another fed herself more than usual. The patients spent more time with dinner when music was played. Dinner music made the patients eat more calmly. Music as a nursing tool is an intervention that is simple to realize and worth trying. A tentative conclusion of this study is that music can beneficially affect restless and agitated demented patients.


Schizophrenia Research | 1999

The synaptic-vesicle-specific proteins rab3a and synaptophysin are reduced in thalamus and related cortical brain regions in schizophrenic brains

Pia Davidsson; Johan Gottfries; Nenad Bogdanovic; Rolf Ekman; Ingvar Karlsson; Carl-Gerhard Gottfries; Kaj Blennow

Two synaptic-vesicle proteins, rab3a and synaptophysin, have been studied on post-mortem brain tissues of schizophrenics and healthy controls. We found significantly reduced levels of rab3a in thalamus (p<0.001); for both proteins in gyrus cinguli and hippocampus (p<0.0001); for rab3a in frontal and parietal cortex (p<0.05); and no differences in temporal cortex or cerebellum in schizophrenics compared with controls. Reduced synaptic density may be a prominent feature of the molecular neuropathology of schizophrenia.


Dementia and Geriatric Cognitive Disorders | 1998

Propentofylline in the Treatment of Alzheimer’s Disease and Vascular Dementia: A Review of Phase III Trials

Matthias Rother; Timo Erkinjuntti; Martin Roessner; Barbara Kittner; Jan Marcusson; Ingvar Karlsson

Propentofylline, a neuroprotective glial cell modulator, has been shown in preclinical studies to address some of the common pathological processes of Alzheimer’s disease (AD) and vascular dementia (VaD), including glial cell activation and increased production of cytokines, free radicals, and glutamate. To examine whether propentofylline (300 mg t.i.d. taken 1 h before meals) would provide beneficial effects in patients with AD and/or VaD, 901 patients with mild-to-moderate AD and 359 patients with mild-to-moderate VaD were enrolled in four double-blind, placebo-controlled, randomized studies ranging in duration from 6 months to 56 weeks. Propentofylline was found to provide consistent improvements over placebo in efficacy assessments for both AD and VaD patients. In addition, results from a drug withdrawal study suggested that propentofylline does not merely relieve dementia symptoms but slows the progression of the disease itself. Propentofylline had a good safety profile and was generally well tolerated.


Journal of Geriatric Psychiatry and Neurology | 1996

Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia

Anders Wallin; Åke Edman; Kaj Blennow; Carl-Gerhard Gottfries; Ingvar Karlsson; Björn Regland; Magnus Sjögren

A method for clinical examination of patients with dementia, stepwise comparative status analysis (STEP), is presented. It combines psychiatric and neurologic status examination methods to identify certain common dementia symptoms by which the patients regional brain symptom profile can be determined. Fifty status variables (items) are estimated with respect to occurrence and severity. The analysis is performed in three steps. The scores on the primary variables reflect observations of single dementia symptoms. These scores form the basis for the assessment of the ‘compound’ variables, which in turn form the basis for evaluation of the ‘complex’ variables, one of which describes the patients regional (predominant) brain syndrome (subcortical, frontosubcortical, frontal, frontoparietal, parietal, or global). In 96 mildly and moderately demented inpatients, the global (42%) and frontosubcortical (31%) were the most common. Ninety-one percent of the patients with vascular dementia had a predominant frontal and/or subcortical symptomatology


Neuroscience | 1991

Monoamine oxidase B in brains from patients with Alzheimer's disease: A biochemical and autoradiographical study

S. S. Jossan; Per-Göran Gillberg; C. G. Gottfries; Ingvar Karlsson; Lars Oreland

In vitro quantitative autoradiography using [3H]L-deprenyl, an irreversible and preferential inhibitor of monoamine oxidase B, was performed to investigate the localization of the enzyme in brains from senile dementia of Alzheimer type and control cases. Brains from three male patients with the clinical diagnosis of senile dementia of Alzheimer type and from three male control patients, without any known clinical history of neurological disorder, were obtained at autopsy. Cryosections of 100 microns thickness were mounted on gelatinized glass plates and dried over desiccant for one week at -20 degrees C. The sections were incubated with 10 nM [3H]L-deprenyl for 1 h and then exposed to film for four weeks. The autoradiographs were analysed by computer-assisted densitometry. Monoamine oxidase-B activities were also estimated in 1% homogenates from 10 different regions, using 10 microM beta-[ethyl-14C]phenylethylamine, in order to study the consonance between the autoradiographical and biochemical techniques. Both [3H]L-deprenyl binding and monoamine oxidase-B activities in senile dementia of Alzheimer type were higher than in the controls in all brain regions studied. The increase was highest in the white matter (about 70%) and in the order of 20-50% in the various gray matter regions. A high correlation coefficient (r approximately 0.9) was obtained between [3H]L-deprenyl binding and monoamine oxidase-B activity, both in the senile dementia of Alzheimer type and in the control brains.


Acta Neurologica Scandinavica | 2009

Blood brain barrier function in vascular dementia

Anders Wallin; Kaj Blennow; Pam Fredman; C. G. Gottfries; Ingvar Karlsson; Lars Svennerholm

To investigate blood‐brain barrier (BBB) function measured as an albumin ratio (cerebrospinal fluid/serum) in vascular dementia (VD) samples from 53 patients and 30 healthy controls were analysed. The VD group showed a higher mean albumin ratio than controls (8.5 ± 3.8 and 5.7 ± 2.1, respectively). The albumin ratio did not correlate significantly with age, nor with individual clinical vascular factors. The results of the present study suggest that the altered BBB might be a consequence of small vessel disorder rather than evidence of infarcts.


Acta Neurologica Scandinavica | 1989

Decreased myelin lipids in Alzheimer's disease and vascular dementia

Anders Wallin; C. G. Gottfries; Ingvar Karlsson; Lars Svennerholm

ABSTRACT— The lipid composition of white matter and myelin from the semioval centre was studied in autopsy material from cases with Alzheimers disease (AD) (n= 11), vascular dementia (VD) (n= 7), and age‐matched controls (n= 11). In AD and VD the white matter content of phospholipids and cholesterol was reduced to 72–76% of the control values (P < 0.01), the diminution of cerebrosides and sulphatides was more pronounced (55–69%) (P < 0.001) while the concentration of gangliosides did not change significantly (87–90%). The myelin composition was the same in the 3 groups, suggesting that the white matter involvement is not caused by alteration of the myelin structure. The altered lipid composition in white matter in AD and VD suggests that the myelin sheath is the primary lesion site.

Collaboration


Dive into the Ingvar Karlsson's collaboration.

Top Co-Authors

Avatar

Kaj Blennow

Sahlgrenska University Hospital

View shared research outputs
Top Co-Authors

Avatar

Anders Wallin

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Görel Bråne

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pam Fredman

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar

Björn Regland

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge